Sematilide is a class III antiarrhythmic agent that selectively blocks the IKr potassium channel; it exhibits concentration-dependent inhibition of the delayed rectifier K⁺ current (IC₅₀ = 25 μM); it demonstrates antiarrhythmic effects in a canine model of arrhythmia at intravenous doses of 0.3 and 3.0 mg/kg.